TOP - November 2019, Vol 12, No 4
The November issue of The Oncology Pharmacist features important news and insights for today’s oncology pharmacists.
Noninvasive Molecular Diagnosis Using Circulating DNA Sequencing Improves Outcomes in Cholangiocarcinoma Management
Diagnosis of cholangiocarcinoma (CCA) is often identified at a late stage. Analyzing the tumorspecific mutation profile of a patient with CCA can improve the diagnosis and treatment for the individual patient.
Patient-centered clinical pathways may hold the promise of truly personalized medicine, improving value-based care and clinical outcomes.
Treatment with the immune checkpoint inhibitor pembrolizumab (Keytruda) dramatically improved 5-year survival for patients with advanced non–small-cell lung cancer (NSCLC) compared with expected survival in the preimmunotherapy era.
Ovarian cancer is a very difficult disease to diagnose and is the most lethal gynecologic malignancy, being the fifth leading cause of cancer death in women in the United States.
This section provides a brief overview of new cancer drugs or new indications approved by the FDA between September 17 and September 26, 2019.
Lost Earnings from Cancer-Related Deaths Cost the United States $94 Billion in 2015
Chicago, IL—Tumor-specific antigens provide personalized targets for immunotherapy. Neoantigen vaccines are a new type of immunotherapy that can elicit immune response and achieve remission. Evidence is compelling to support neoantigens as the target of effective immune responses against cancer and to support an association between neoantigen load with improved clinical outcome, said Patrick Alexander Ott, MD, PhD, Clinical Director, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, at ASCO 2019.
San Diego, CA—Great progress has been made in the fight against cancer, but not all patients have benefited equally. Disparities exist among specific populations in terms of survival and cancer-related mortality, incidence and prevalence, as well as adverse health conditions, according to Karen M. Winkfield, MD, PhD, Director, Office of Cancer Health Equity, Wake Forest Baptist Medical Center Comprehensive Cancer Center, Winston-Salem, NC. Dr Winkfield discussed the topic at the 2019 ASCO Quality Care Symposium.
People who are less engaged in their own medical care have more negative health consequences, including higher readmission rates, poor care coordination, and less confidence.
Page 1 of 2
Results 1 - 10 of 13
Results 1 - 10 of 13